References
- Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: part 1. Consequences of policy decisions to respond using nonpharmaceutical interventions. Expert Rev Vaccines. 2021 Apr;20(4):465–481.
- Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Med J Med. 2008;10(8):190.
- World Health Organization. 14th Meeting of the Global Commission for Certification of Poliomyelitis Eradication (GCC), Bali, Indonesia, 20-21 September, 2015 Summary of findings, decisions and recommendations 2015 [cited 2021 Jul 22]. Available from: http://polioeradication.org/wp-content/uploads/2016/07/1Report.pdf
- World Health Organization. Report from the Twentieth meeting of the global commission for certification of poliomyelitis eradication, Geneva, Switzerland, 17-18 October 2019 [cited 2019 Dec 31]. Available from: http://polioeradication.org/wp-content/uploads/2016/07/20th-meeting-of-the-Global-Commission-for-the-Certification-of-Eradication-of-Poliomyelitis-17-18-October-2019.pdf
- World Health Organization. Wild poliovirus list: list of wild poliovirus by country and year 2022. [cited 2022 Sep 20]. Available from: https://polioeradication.org/wp-content/uploads/2022/09/weekly-polio-analyses-WPV-202200920.pdf
- Badizadegan K, Kalkowska DA, Thompson KM. Polio by the numbers - A global perspective. J Infect Dis. 2022 Apr 13.https://doi.org/10.1093/infdis/jiac130
- Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol. 2005 August;162(4):358–372.
- Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Expert review on poliovirus immunity and transmission. Risk Anal. 2013;33(4):544–605.
- Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26(6):1471–1505.
- Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010 Dec 1;172(11):1213–1229.
- Kew OM, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296(5566):356–359.
- Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, et al. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;23(4):703–749.
- Kew OM, Sutter RW, De Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann Rev Microbiol. 2005;59(1):587–635.
- Global Polio Eradication Initiative. Classification and reporting of vaccine-derived polioviruses (VDPV). 2015 August. Available from: https://polioeradication.org/wp-content/uploads/2016/09/Reporting-and-Classification-of-VDPVs_Aug2016_EN.pdf
- World Health Organization Global Polio Eradication Initiative. Standard operating procedures - Responding to a poliovirus event or outbreak – version 4 2022 [cited 2022 Aug 20]. Available from: https://polioeradication.org/wp-content/uploads/2022/07/Standard-Operating-Procedures-For-Responding-to-a-Poliovirus-Event-Or-Outbreak-20220807-EN-Final.pdf
- Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis. 2015;15(379). DOI:10.1186/s12879-015-1115-5
- Kalkowska DA, Pallansch MA, Thompson KM. Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiol Infect. 2019;147:e295.
- Duintjer Tebbens RJ, Pallansch MA, Wassalik SGF, et al. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis. 2015;15(389). DOI:10.1186/s12879-015-1112-8
- Kalkowska DA, Wassilak SGF, Cochi SL, et al. Global transmission of live polioviruses: updated integrated dynamic modeling of the polio endgame. Risk Anal. 2021;41(2):248–265.
- Thompson KM, Pallansch MA, Duintjer Tebbens RJ, et al. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal. 2013;33(4):647–663.
- Thompson KM, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of live polioviruses. Vaccine. 2015 March 24;33(3):1568–1577.
- Dowdle WR, de Gourville E, Kew OM, et al. Polio eradication: the OPV paradox. Rev Med Virol. 2003 Sep-Oct;13(5):277–291.
- World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1), WHO: Geneva, 19–24 May 2008 Geneva: World Health Organization; [cited 2019 Jun 4]. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf
- Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - Worldwide, 2016. MMWR. 2016 September 9;65(35):934–938.
- Thompson KM. Polio eradication: what kind of world do we want? Lancet Infect Dis. 2022 Oct 11;22(2):161–163.
- World Health Organization Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus 2022 [cited 2022 September 20 2022]. Available from: https://polioeradication.org/wp-content/uploads/2022/09/weekly-polio-analyses-cVDPV-20220920.pdf
- Macklin G, Peak C, Eisenhawer M, et al. Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): novel Oral Polio Vaccine type 2 (nOPV2) experience. Vaccine. 2022 Mar 17;S0264-410X(22):5.
- Kalkowska DA, Pallansch MA, Cochi SL, et al. Updated characterization of post-OPV cessation risks: lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart. Risk Anal. 2021;41(2):320–328.
- Kalkowska DA, Pallansch MA, Wilkinson A, et al. Updated characterization of poliovirus outbreak response strategies for 2019-2029: impacts of the use of novel OPV2 strains. Risk Anal. 2021;41(2):329–348.
- Kalkowska DA, Pallansch MA, Wassilak SGF, et al. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine. 2021 May 13. DOI:10.1016/j.vaccine.2021.04.061.
- Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. Lancet. 2007 Apr 21;369(9570):1363–1371.
- Arita I, Nakane M, Fenner F. Public health. Is polio eradication realistic? Science. 2006 May 12;312(5775):852–854.
- World Health Organization. Poliomyelitis vaccination coverage 2022 [cited 2022 May 17]. Available from: https://immunizationdata.who.int/pages/coverage/pol.html
- World Health Organization Global Polio Eradication Initiative. Polio eradication strategy 2022-2026: delivering on a promise 2021 [cited 2021 Jun 11]. Available from: https://polioeradication.org/wp-content/uploads/2021/06/polio-eradication-strategy-2022-2026-pre-publication-version-20210609.pdf
- Thompson KM, Duintjer Tebbens RJ, Pallansch MA, et al. Polio eradicators use integrated analytical models to make better decisions. Interfaces. 2015 January-February;45(1):5–25.
- Thompson KM, Kalkowska DA. An updated economic analysis of the global polio eradication initiative. Risk Anal. 2021;41(2):393–406.
- Zimmermann M, Hagedorn B, Lyons H. Projection of costs of polio eradication compared to permanent control. J Infect Dis. 2020 Sep 30;221(4):561–565.
- Kalkowska DA, Thompson KM. Health and economic outcomes associated with polio vaccine policy options: 2019-2029. Risk Anal. 2021;41(2):364–375.
- Kalkowska DA, Badizadegan K, Thompson KM. Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan. Risk Anal. 2022. In press. DOI: 10.1111/risa.13983.
- Duintjer Tebbens RJ, Thompson KM. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.Expert Rev Vaccines. 2018 2018 August 03;17(8):739–751.
- Thompson KM, Kalkowska DA. Potential future use, costs, and value of poliovirus vaccines. Risk Anal. 2021 Feb;41(2):349–363.
- Kalkowska DA, Thompson KM. Expected implications of globally-coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV. Risk Anal. 2021;41(2):312–319.
- Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. Economic analysis of the global polio eradication initiative. Vaccine. 2011 December 16;29(2):334–343.
- Thompson KM, Kalkowska DA. Reflections on modeling poliovirus transmission and the polio eradication endgame. Risk Anal. 2021 Feb;41(2):229–247.
- Thompson KM, Wallace GS, Duintjer Tebbens RJ, et al. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. 433021. 2012;127(1):23–37.
- Anis E, Kopel E, Singer S, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveillance. 2013;18(38):20586.
- Rachlin A, Patel JC, Burns CC, et al. Progress toward polio eradication - worldwide, January 2020-April 2022. MMWR Morb Mortal Wkly Rep. 2022 May 13;71(19):650–655.
- Chumakov K, Ehrenfeld E, Agol VI, et al. Polio eradication at the crossroads. Lancet Glob Health. 2021;9(8):E1172–5.
- Marsian J, Fox H, Bahar MW, et al. Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine. Nat Commun. 2017 Aug 15;8(1):245.
- Sherry L, Grehan K, Snowden JS, et al. Comparative molecular biology approaches for the production of poliovirus virus-like particles using pichia pastoris. mSphere. 2020 Mar 11;5(2):2.
- Xu Y, Ma S, Huang Y, et al. Virus-like particle vaccines for poliovirus types 1, 2, and 3 with enhanced thermostability expressed in insect cells. Vaccine. 2019 Apr 17;37(17):2340–2347.
- Bahar MW, Porta C, Fox H, et al. Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. NPJ Vaccines. 2021 Jan 8;6(1):5.
- Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000-2019 to support global polio eradication. Expert Rev Vaccines. 2020;19(7):661–686.
- Kalkowska DA, Pallansch MA, Cochi SL, et al. Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response options. J Infect Dis. 2021 Apr 22;224(9):1529–1538.
- Kalkowska DA, Voorman A, Pallansch MA, et al. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine. 2021 Apr;27. DOI: 10.1016/j.vaccine.2021.04.026
- Global Polio Eradication Initiative. nOPV2: clinical development summary updated June 2022 2022 [2022 Aug 11]. Available from: https://polioeradication.org/wp-content/uploads/2022/06/nOPV2-Clinical-Development-Summary_June-2022-Update_Final-EN.pdf
- World Health Organization. Vaccine-derived poliovirus type 2 (VDPV2) detected in environmental samples in London, UK 2022 [cited 2022 Jul 11]. Available from: https://polioeradication.org/wp-content/uploads/2021/12/weekly-polio-analyses-WPV-20211228.pdf
- Kalkowska DA, Duintjer Tebbens RJ, Grotto I, et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. 2015;211(11):1800–1812.
- Global Polio Eradication Initiative. Investment case 2022–2026. Geneva: Switzerland: World Health Organization; 2022. Available from: https://polioeradication.org/wp-content/uploads/2022/04/GPEI-Investment-Case-2022-2026-Web-EN.pdf.